CERC - セレコ― (Cerecor Inc.) セレコ―

 CERCのチャート


 CERCの企業情報

symbol CERC
会社名 Cerecor Inc (セレコ―)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 Cerecor Inc. is a clinical stage biopharmaceutical company. The Company is engaged in developing drug candidates for patients with neurological and psychiatric disorders. The Company has a portfolio of clinical and preclinical compounds that it is developing for a range of indications including CERC-301 which is an adjunctive treatment for major depressive disorder (MDD); CERC-501 which is for substance use disorders and adjunctive treatment of MDD and CERC-406 which is for the treatment of cognitive impairment. The Company owns the rights to its COMTi platform. Catechol O methyltransferase (COMT) is an enzyme critical for the inactivation and metabolism of dopamine and its inhibition in the brain has applicability in treating subjects with neuropsychiatric conditions including MDD schizophrenia Parkinson''s disease and pathological gambling. Its COMTi platform comprises COMT inhibitors with selectivity for membrane bound COMT which is the dominant form of COMT.   セレコ―は米国の臨床段階のバイオ医薬品会社。神経障害や精神疾患の治療薬の開発に重点を置く。主要候補薬には、大鬱病性障害(MDD)の補助的治療薬の「CERC-301」、大鬱病性障害や物質使用障害の補助的治療薬「CERC-501」、後遺認知障害症のための「CERC-406」がある。本社はメリ―ランド州ボルチモア。   
本社所在地 400 E. Pratt Street Suite 606 Baltimore MD 21202 USA
代表者氏名 Uli Hacksell ウリ・ハッスル
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 410-522-8707
設立年月日 40544
市場名 NASDAQ Small Cap
ipoyear 2015年
従業員数
url www.cerecor.com
nasdaq_url https://www.nasdaq.com/symbol/cerc
adr_tso
EBITDA EBITDA(百万ドル) 14.46257
終値(lastsale) 4.39
時価総額(marketcap) 174191270.95
時価総額 時価総額(百万ドル) 183.87190
売上高 売上高(百万ドル) 36.53905
企業価値(EV) 企業価値(EV)(百万ドル) 197.11869
当期純利益 当期純利益(百万ドル) 7.93865
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Cerecor Inc revenues increased from $542K to $9.3M. Net loss increased from $3.8M to $9.9M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Change in fair value of warrant increase from $2K to $295K (expense) Interest expense net increase from $83K to $343K (expense).

 CERCのテクニカル分析


 CERCのニュース

   Thinking about buying stock in Cerecor, Surface Oncology, SINTX Technologies, Clearpoint Neuro, or Senseonics Holdings?  2021/03/02 14:31:00 PR Newswire
NEW YORK, March 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CERC, SURF, SINT, CLPT, and SENS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure and Mortality in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS  2021/03/02 12:00:00 GlobeNewswire
Final analysis inclusive of the 60-day safety update in the randomized placebo-controlled study demonstrated CERC-002 was statistically significant in…
   Power Ministry reduces discom penalties to 5% over SBI lending rate  2021/02/24 08:55:38 Economic Times India
The government has lowered the late payment fee chargeable by power and transmission developers from distribution companies by linking it to State Bank of India's lending rate against the current 18%.The Electricity (Late Payment Surcharge) Rules 2021 exclude existing power plants and transmission systems whose tariffs have been determined through competitive bidding.The rules bar electricity distribution companies with any outstanding bills after seven months from due date from procuring power from power exchanges or grant of short -term open access. The rules came into force on Monday when they were notified.The gazette notification issued by the power ministry evoked mixed response from the industry as it supersedes regulations of the Central Electricity Regulatory Commission (CERC) and also the power purchase/transmission agreements. CERC chairperson P K Pujari had in October sent a statutory advice to the government against issuance of the rules citing jurisdictional overlap.The power distribution companies welcomed reduction in late payment fee while electricity generation plants and transmission companies with regulated tariffs said lowering of the penalty rates interest would discourage timely payments by states.
   The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts  2021/02/23 12:25:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acceleron Pharma Inc (NASDAQ: XLRN ) Akari Therapeutics PLC (NASDAQ: AKTX ) Annexon Inc (NASDAQ: ANNX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) AxoGen, Inc (NASDAQ: AXGN ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Celcuity Inc (NASDAQ: CELC ) (announced a $20 million common stock offering) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerecor Inc (NASDAQ: CERC ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) DermTech Inc (NASDAQ: DMTK ) Gemini Therapeutics Inc (NASDAQ: GMTX ) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) (announced NDA submissions for two indications for Caplyta - as monotherapy and as adjunctive therapy with lithium or valproate for the treatment of depressive episodes associated with bipolar I or II disorder) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mereo BioPharma Group plc – ADR (NASDAQ: MREO ) Nantkwest Inc (NASDAQ: NK ) Orthofix Medical Inc (NASDAQ: OFIX ) PAVmed Inc (NASDAQ: PAVM ) (reacted to its fourth-quarter results) Pharvaris BV (NASDAQ: PHVS ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) United Therapeutics Corporation (NASDAQ: UTHR ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 22) bluebird bio Inc (NASDAQ: BLUE ) Pharming Group (NASDAQ: PHAR ) Talis Biomedical Corp (NASDAQ: TLIS ) Vallon Pharmaceuticals Inc (NASDAQ: VLON ) Stocks In Focus Surface Oncology Exercises Option to License Vaccinex Platform-discovered Anti-CCR8 Antibody Vaccinex Inc (NASDAQ: VCNX ) announced that Surface Oncology Inc (NASDAQ: SURF ) will be exercising its option to license the anti-CCR8 antibody discovered via Vaccinex's ActivMAb antibody discovery and novel viral display platform.
   CERC norms: ‘Market coupling’ mechanism for spot power market gets a leg-up  2021/02/18 23:45:00 The Financial Express
Analysts said the new regulations will help increase the share of spot power in electricity purchased by discoms and large industrial consumers.
   Thinking about buying stock in Cerecor, Surface Oncology, SINTX Technologies, Clearpoint Neuro, or Senseonics Holdings?  2021/03/02 14:31:00 PR Newswire
NEW YORK, March 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CERC, SURF, SINT, CLPT, and SENS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure and Mortality in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS  2021/03/02 12:00:00 GlobeNewswire
Final analysis inclusive of the 60-day safety update in the randomized placebo-controlled study demonstrated CERC-002 was statistically significant in…
   Power Ministry reduces discom penalties to 5% over SBI lending rate  2021/02/24 08:55:38 Economic Times India
The government has lowered the late payment fee chargeable by power and transmission developers from distribution companies by linking it to State Bank of India's lending rate against the current 18%.The Electricity (Late Payment Surcharge) Rules 2021 exclude existing power plants and transmission systems whose tariffs have been determined through competitive bidding.The rules bar electricity distribution companies with any outstanding bills after seven months from due date from procuring power from power exchanges or grant of short -term open access. The rules came into force on Monday when they were notified.The gazette notification issued by the power ministry evoked mixed response from the industry as it supersedes regulations of the Central Electricity Regulatory Commission (CERC) and also the power purchase/transmission agreements. CERC chairperson P K Pujari had in October sent a statutory advice to the government against issuance of the rules citing jurisdictional overlap.The power distribution companies welcomed reduction in late payment fee while electricity generation plants and transmission companies with regulated tariffs said lowering of the penalty rates interest would discourage timely payments by states.
   The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts  2021/02/23 12:25:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acceleron Pharma Inc (NASDAQ: XLRN ) Akari Therapeutics PLC (NASDAQ: AKTX ) Annexon Inc (NASDAQ: ANNX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) AxoGen, Inc (NASDAQ: AXGN ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Celcuity Inc (NASDAQ: CELC ) (announced a $20 million common stock offering) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerecor Inc (NASDAQ: CERC ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) DermTech Inc (NASDAQ: DMTK ) Gemini Therapeutics Inc (NASDAQ: GMTX ) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) (announced NDA submissions for two indications for Caplyta - as monotherapy and as adjunctive therapy with lithium or valproate for the treatment of depressive episodes associated with bipolar I or II disorder) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mereo BioPharma Group plc – ADR (NASDAQ: MREO ) Nantkwest Inc (NASDAQ: NK ) Orthofix Medical Inc (NASDAQ: OFIX ) PAVmed Inc (NASDAQ: PAVM ) (reacted to its fourth-quarter results) Pharvaris BV (NASDAQ: PHVS ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) United Therapeutics Corporation (NASDAQ: UTHR ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 22) bluebird bio Inc (NASDAQ: BLUE ) Pharming Group (NASDAQ: PHAR ) Talis Biomedical Corp (NASDAQ: TLIS ) Vallon Pharmaceuticals Inc (NASDAQ: VLON ) Stocks In Focus Surface Oncology Exercises Option to License Vaccinex Platform-discovered Anti-CCR8 Antibody Vaccinex Inc (NASDAQ: VCNX ) announced that Surface Oncology Inc (NASDAQ: SURF ) will be exercising its option to license the anti-CCR8 antibody discovered via Vaccinex's ActivMAb antibody discovery and novel viral display platform.
   CERC norms: ‘Market coupling’ mechanism for spot power market gets a leg-up  2021/02/18 23:45:00 The Financial Express
Analysts said the new regulations will help increase the share of spot power in electricity purchased by discoms and large industrial consumers.
   Thinking about buying stock in Cerecor, Surface Oncology, SINTX Technologies, Clearpoint Neuro, or Senseonics Holdings?  2021/03/02 14:31:00 PR Newswire
NEW YORK, March 2, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CERC, SURF, SINT, CLPT, and SENS. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link….
   Cerecor Announces CERC-002 Significantly Reduced Respiratory Failure and Mortality in Phase 2 Clinical Trial in Patients Hospitalized with COVID-19 ARDS  2021/03/02 12:00:00 GlobeNewswire
Final analysis inclusive of the 60-day safety update in the randomized placebo-controlled study demonstrated CERC-002 was statistically significant in…
   Power Ministry reduces discom penalties to 5% over SBI lending rate  2021/02/24 08:55:38 Economic Times India
The government has lowered the late payment fee chargeable by power and transmission developers from distribution companies by linking it to State Bank of India's lending rate against the current 18%.The Electricity (Late Payment Surcharge) Rules 2021 exclude existing power plants and transmission systems whose tariffs have been determined through competitive bidding.The rules bar electricity distribution companies with any outstanding bills after seven months from due date from procuring power from power exchanges or grant of short -term open access. The rules came into force on Monday when they were notified.The gazette notification issued by the power ministry evoked mixed response from the industry as it supersedes regulations of the Central Electricity Regulatory Commission (CERC) and also the power purchase/transmission agreements. CERC chairperson P K Pujari had in October sent a statutory advice to the government against issuance of the rules citing jurisdictional overlap.The power distribution companies welcomed reduction in late payment fee while electricity generation plants and transmission companies with regulated tariffs said lowering of the penalty rates interest would discourage timely payments by states.
   The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts  2021/02/23 12:25:48 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acceleron Pharma Inc (NASDAQ: XLRN ) Akari Therapeutics PLC (NASDAQ: AKTX ) Annexon Inc (NASDAQ: ANNX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) AxoGen, Inc (NASDAQ: AXGN ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Celcuity Inc (NASDAQ: CELC ) (announced a $20 million common stock offering) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerecor Inc (NASDAQ: CERC ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) DermTech Inc (NASDAQ: DMTK ) Gemini Therapeutics Inc (NASDAQ: GMTX ) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) (announced NDA submissions for two indications for Caplyta - as monotherapy and as adjunctive therapy with lithium or valproate for the treatment of depressive episodes associated with bipolar I or II disorder) iTeos Therapeutics Inc (NASDAQ: ITOS ) Mereo BioPharma Group plc – ADR (NASDAQ: MREO ) Nantkwest Inc (NASDAQ: NK ) Orthofix Medical Inc (NASDAQ: OFIX ) PAVmed Inc (NASDAQ: PAVM ) (reacted to its fourth-quarter results) Pharvaris BV (NASDAQ: PHVS ) Pliant Therapeutics Inc (NASDAQ: PLRX ) RedHill Biopharma Ltd (NASDAQ: RDHL ) Silence Therapeutics ADR Representing 3 Ord Shs (NASDAQ: SLN ) United Therapeutics Corporation (NASDAQ: UTHR ) Vistagen Therapeutics Inc (NASDAQ: VTGN ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Feb. 22) bluebird bio Inc (NASDAQ: BLUE ) Pharming Group (NASDAQ: PHAR ) Talis Biomedical Corp (NASDAQ: TLIS ) Vallon Pharmaceuticals Inc (NASDAQ: VLON ) Stocks In Focus Surface Oncology Exercises Option to License Vaccinex Platform-discovered Anti-CCR8 Antibody Vaccinex Inc (NASDAQ: VCNX ) announced that Surface Oncology Inc (NASDAQ: SURF ) will be exercising its option to license the anti-CCR8 antibody discovered via Vaccinex's ActivMAb antibody discovery and novel viral display platform.
   CERC norms: ‘Market coupling’ mechanism for spot power market gets a leg-up  2021/02/18 23:45:00 The Financial Express
Analysts said the new regulations will help increase the share of spot power in electricity purchased by discoms and large industrial consumers.

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 セレコ― CERC Cerecor Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)